Next 10 |
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ...
2024-05-07 10:55:22 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Esperion Therapeutics (NASDAQ: ESPR ) just reported results for the first quarter of 2024. Esperion Therapeutics reported earnings per share of 34 cents. This was above th...
2024-05-07 10:45:03 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $10.43 with volume of 34,045,104 and a one day change of $0.10 (0.98%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...
2024-05-07 10:05:19 ET Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Conference Call May 07, 2024 08:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - President & Chief Executive Officer Ben Ha...
A look at the top 10 most actives in the United States Nuwellis Inc. (NUWE) rose 60.3% to $0.2741 on volume of 66,284,094 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 21.1% to $0.05 on volume of 64,247,106 shares Clearmind Medicine Inc. (CMND) rose 37.6% to $1.61 on volume ...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
2024-05-07 06:04:21 ET More on Esperion Therapeutics A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics Esperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groups Read the full article on Seeking Al...
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Ex...
2024-05-06 10:34:16 ET More on Esperion Therapeutics A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics Esperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groups Esperion stock jumps 18% in wake of F...
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website . JMP Securities’ Life Sc...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ...
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consens...